TACC3  overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors

Jun-chuang He; Wei Yao; Jian-ming Wang; Peter Schemmer; Yan Yang; Yan Liu; Ya-wei Qian; Wei-peng Qi; Jian Zhang; Qi Shen; Tao Yang

doi:10.18632/oncotarget.12254

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors

Jun-chuang He, Wei Yao, Jian-ming Wang _, Peter Schemmer, Yan Yang, Yan Liu, Ya-wei Qian, Wei-peng Qi, Jian Zhang, Qi Shen and Tao Yang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:75441-75456. https://doi.org/10.18632/oncotarget.12254

Metrics: PDF 2425 views | HTML 2327 views | ?

Abstract

Jun-chuang He1,*, Wei Yao1,*, Jian-ming Wang1, Peter Schemmer2, Yan Yang1, Yan Liu1, Ya-wei Qian1, Wei-peng Qi1, Jian Zhang1, Qi Shen1, Tao Yang1

1Department of Biliary and Pancreatic Surgery/Cancer Research Center Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China

2Department of General and Transplant Surgery, University Hospital Heidelberg, Heidelberg 69120, Germany

*These authors have contributed equally to this work

Correspondence to:

Jian-ming Wang, email: [email protected]

Keywords: histone deacetylase (HDAC), HDAC inhibitors (HDACIs), microarray, transforming acidic coiled-coil-containing protein 3 (TACC3), cholangiocarcinoma (CCA)

Received: March 19, 2016 Accepted: September 13, 2016 Published: September 26, 2016

ABSTRACT

Histone deacetylases (HDACs) have been implicated in multiple malignant tumors, and HDAC inhibitors (HDACIs) exert anti-cancer effects. However, the expression of HDACs and the anti-tumor mechanism of HDACIs in cholangiocarcinoma (CCA) have not yet been elucidated. In this study, we found that expression of HDACs 2, 3, and 8 were up-regulated in CCA tissues and those patients with high expression of HDAC2 and/or HDAC3 had a worse prognosis. In CCA cells, two HDACIs, trichostatin (TSA) and vorinostat (SAHA), suppressed proliferation and induced apoptosis and G2/M cycle arrest. Microarray analysis revealed that TACC3 mRNA was down-regulated in CCA cells treated with TSA. TACC3 was highly expressed in CCA tissues and predicted a poor prognosis in CCA patients. TACC3 knockdown induced G2/M cycle arrest and suppressed the invasion, metastasis, and proliferation of CCA cells, both in vitro and in vivo. TACC3 overexpression reversed the effects of its knockdown. These findings suggest TACC3 may be a useful prognostic biomarker for CCA and is a potential therapeutic target for HDACIs.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12254

Publication Alerts

Research Papers:

TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors

Abstract